Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2019 01:00 ET | Source: Addex Therapeutics

Addex to Present During the Swiss Biotech Day

Geneva, Switzerland, May 6, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will...
April 30, 2019 01:00 ET | Source: Addex Therapeutics

Addex Reports 2018 Full Year Audited Results and Provides Corporate Update

Robust cash position of CHF41.7 million providing runway through 2021Dipraglurant on track to start pivotal registration study in PD-LID by end of yearStrengthened team of clinical and preclinical...
April 29, 2019 01:00 ET | Source: Addex Therapeutics

Addex to Announce 2018 Full Year Audited Results on April 30, 2019

Geneva, Switzerland, April 29, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will report its...
March 21, 2019 02:00 ET | Source: Addex Therapeutics

Addex to Participate in the BIOEurope Spring Conference

Geneva, Switzerland, March 21, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer and...
March 11, 2019 02:00 ET | Source: Addex Therapeutics

Addex to Present at the Cowen 39th Annual Health Care Conference on March 13, 2019

Geneva, Switzerland, 11 March 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the company’s CEO,...
March 08, 2019 01:00 ET | Source: Addex Therapeutics

Addex Trading Update in Accordance with Art. 53 of the SIX Listing Rules (Ad hoc publicity)

Geneva, Switzerland, 8 March 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today an unaudited operating loss...
February 14, 2019 02:00 ET | Source: Addex Therapeutics

Addex and Indivior to Accelerate Additional GABAB PAM Compounds for Addiction as Indivior Elects to Stop Development of ADX71441

Geneva, Switzerland, 14th February 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, and Indivior PLC (LON: INDV)...
January 07, 2019 01:00 ET | Source: Addex Therapeutics

Addex Trading Update: Completes 2018 with Strong Cash Position

Geneva, Switzerland, 7th January 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has completed...
November 22, 2018 01:00 ET | Source: Addex Therapeutics

Addex Van Leeuwenhoeck Equity Research Report Highlights Deep Pipeline Well Funded through Pivotal Registration Study and Increases Price Target to CHF 14

Geneva, Switzerland, 22 November 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the independent...
November 12, 2018 01:00 ET | Source: Addex Therapeutics

Addex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference

Geneva, Switzerland, 12th November 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer,...